Enfusion (NYSE:ENFN) Reaches New 12-Month High – Should You Buy?

Enfusion, Inc. (NYSE:ENFN) reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $11.80 and last traded at $11.38, with a volume of 160693 shares. The stock had previously closed at $11.07.

Analyst Ratings Changes

Several brokerages recently commented on ENFN. William Blair reiterated a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. Stifel Nicolaus raised their price target on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Finally, Piper Sandler lifted their price objective on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research note on Monday, December 23rd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.50.

Enfusion Stock Performance

The firm’s 50-day simple moving average is $10.79 and its 200-day simple moving average is $9.61. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of 284.95, a price-to-earnings-growth ratio of 1.81 and a beta of 0.96.

Insider Buying and Selling

In related news, CFO Bradley Herring sold 4,134 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total value of $41,877.42. Following the completion of the transaction, the chief financial officer now directly owns 266,369 shares of the company’s stock, valued at $2,698,317.97. This trade represents a 1.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Neal Pawar sold 21,801 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total transaction of $218,664.03. Following the completion of the sale, the chief operating officer now directly owns 1,143,544 shares in the company, valued at $11,469,746.32. This trade represents a 1.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 57,367 shares of company stock valued at $591,335 over the last three months. 36.44% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Enfusion by 43.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 33,721 shares of the company’s stock worth $347,000 after buying an additional 10,173 shares in the last quarter. Squarepoint Ops LLC raised its stake in Enfusion by 136.2% during the fourth quarter. Squarepoint Ops LLC now owns 35,633 shares of the company’s stock worth $367,000 after acquiring an additional 20,550 shares in the last quarter. State of Wyoming lifted its holdings in shares of Enfusion by 52.7% during the fourth quarter. State of Wyoming now owns 76,814 shares of the company’s stock valued at $791,000 after acquiring an additional 26,525 shares during the period. Silvercrest Asset Management Group LLC acquired a new stake in shares of Enfusion in the 4th quarter valued at $4,300,000. Finally, ProShare Advisors LLC bought a new stake in shares of Enfusion in the 4th quarter worth about $144,000. Institutional investors own 81.05% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.